Myocet

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2016
02420012016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Despite the success in treating the majority of children with newly diagnosed acute leukemia, children with relapsed or… (More)
Is this relevant?
2011
2011
BACKGROUND Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic… (More)
Is this relevant?
2009
2009
BACKGROUND Trastuzumab provides considerable therapeutic benefits in the adjuvant setting of breast cancer. However, its use is… (More)
Is this relevant?
2006
2006
17506 Background: The majority of patients (pts) with diffuse large B-cell lymphoma (DLBCL) are elderly and may have limited… (More)
Is this relevant?
2005
2005
BACKGROUND We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of non-pegylated liposome… (More)
Is this relevant?
2004
2004
Liposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and gastrointestinal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 5
  • table 2
Is this relevant?
2004
2004
OBJECTIVE To ascertain the efficacy and tolerability of non-pegylated liposomal doxorubicin (Myocet) and epirubicin combined with… (More)
Is this relevant?
2003
2003
Myocet (TLC D-99) is a liposomal formulation of the anti-neoplastic drug doxorubicin with an improved therapeutic index compared… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND The objective of this study was to compare the efficacy and toxicity of the liposome-encapsulated doxorubicin, TLC D… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in… (More)
Is this relevant?